| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
– PACE-1 trial of ALTO-207 in treatment-resistant depression (TRD) on track; topline data in 2H 2027 – |
| 27 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
As you know, you are currently employed at Alto Neuroscience, Inc. (the “Company”) as Chief Financial Officer and Chief Business Officer pursuant to the terms of an offer letter dated November 20, 2023, as amended by a letter agreement d... |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
– ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoing potentially registrational Phase 2b trial; topline Phase 2b dat... |
| 14 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
Alto Neuroscience, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall... |
| 13 Jul 2026 |
8-K: Results of Operations and Financial Condition; Other Events
The information disclosed under the heading “Cash, Cash Equivalents and Restricted Cash as of June 30, 2026” under Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference and shall not be deemed “filed” for purpo... |
| 28 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 27, 2026, the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller... |
| 13 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights t... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
– Phase 2b clinical trial of ALTO-207 in treatment-resistant depression (TRD) initiated – |
| 01 Apr 2026 |
8-K: Other Events
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements |
| 16 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 16, 2026, by and among Alto Neuroscience, Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit A attached to this Agreement ... |
| 16 Mar 2026 |
8-K: Results of Operations and Financial Condition
– Acquisition of ALTO-207 targets Treatment-Resistant Depression (TRD) with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 – |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
– Successful outcome from FDA meeting on ALTO-207 in treatment-resistant depression; on track to initiate Phase 2b trial in the first half of 2026 and Phase 3 trial by early 2027 – |
| 20 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 19, 2025, by and among Alto Neuroscience, Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit A attached to this Agreemen... |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
– Acquisition of potentially best-in-class dopamine agonist combination product candidates, including ALTO-207, expands precision psychiatry pipeline; guided by compelling PAX-D study results published in The Lancet Psychiatry – |
| 08 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 3, 2025, the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”) approved an option repricing, which was effective at the close of market on July 3, 2025 (the “Effective Date”). The repricing generally app... |
| 26 Jun 2025 |
8-K: Other Events
Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203 |
| 03 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition; Submission of Matters to a Vote of Security Holders
– Phase 2 proof-of-concept trials remain on track: Topline data expected from ALTO-203 in MDD in the second quarter of 2025 followed by ALTO-101 in schizophrenia in the second half of 2025 – |
| 20 Mar 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
– Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial; topline results expected in mid-2026 – |
| 12 Feb 2025 |
8-K: Other Events
– Interim analysis resulted in a recommendation to continue the study with a total targeted biomarker population of ~200 patients in the final analysis sample – |
Loading...